Immune responses to infection by the human immunodeficiency virus (HIV) and the use of highly active antiretroviral therapy (HAART) to treat HIV infection, contributes to metabolic irregularities in the host.
INTRODUCTION
During HIV infection, host metabolism is influenced among other things by the virus [1] [2] [3] , immune responses [4] [5] [6] and treatment [7, 8] . HAART, primarily used to restore HIV-induced effects, prolongs the lifespan of infected individuals [8] and has subsequently resulted in HIV infection becoming a chronic condition, especially in developed countries. As a result, there has been an increase in the incidence of chronically infected individuals presenting with HIV and treatement-induced metabolic disturbances. Metabolic dysfunction during HIV infection is not a singular event so much so that a combination of metabolic changes can be induced at one time. This combination of metabolic disorders are routinely defined as metabolic syndrome in the relevant literature where the terminology refers to for example insulin resistance, dyslipidaemia, lipodystrophy, and so on, sometimes occurring in concert [9] [10] [11] .
Metabolites associated with HIV and/or HAART-induced metabolic disturbances include glucose, other carbohydrates and lipids. Alterations in the metabolism of carbohydrates (e.g glucose, [12] ) and lipids [13, 14] have been identified very early in AIDS research as key metabolites affected during HIV infection. These early observations were however, made using laborious conventional rather than metabonomics methodologies [15] .
Because metabolites are (i) the end products of all enzymatic/chemical reactions occurring in the body, (ii) altered by infection and treatment, (iii) detectable through analytical techniques and (iv) informative regarding an individual's physiological state [16] , these molecules are being revisited for their role as biomarkers of HIV infection (see studies highlighted in [15) . To date, accurate and reliable markers for the diagnosis of HIV infection, monitoring of disease progression and assessing the success of therapeutic interventions are still lacking [17] . This is because many molecules that are influenced by HIV infection fail to meet the basic requirements of a biomarker (as defined by Kanekar, 2010 [18] as well as Beger and Colatsky, spent on method development. Ostro TM plate procedures are generally also less destructive to metabolites [30] , the plastic used in the manufacture of these plates is inert minimizing leaching of plasticizers. The most novel aspect of these plates are their ability to remove phospholipids from samples. Phospholipids contribute to matrix effects and can accumulate on the chromatographic column ultimately resulting in variable analyte signals.
Phospholipids are also known to cause ion suppression during MS analysis, masking analyte detection [35] .
The aim of this work was to apply an easy to perform SPE protocol (using Ostro TM plates) to better prepare serum samples for improved UPLC-MS biofluid metabonomics data collection.
It was important to demonstrate that the protocols (for sample extraction and data collection) could be applied to randomly collected serum samples (to show that the method applied was able to detect metabolic changes in any patient irrespective of disease status or other possibly confounding factors like age, lifestyle etc) because metabonomics is ultimately aimed at clinical application. In the data presented here, clear differences were observed between the metabolic profiles of the three study groups prior to the use of statistics. These differences were amplified following multivariate analysis. LDA classified the groups as HIV negative, HIV+ and HIV+HAART+ with 100% accuracy. The variances between the groups were mainly explained by molecules involved in lipid and energy metabolism as well as metabolites (e.g. nucleotides ) influenced by treatment of the patients. This is the first time, using Ostro TM plates and a metabonomics approach that the metabolites of drugs used to treat HIVassociated conditions are detected in infected biofluids such as serum.
MATERIALS AND METHODS

Experimental Design and Sample Preparation
A global analysis was done on the sera of HIV-seronegative (HIV negative), HIV-seropositive (HIV+) and HIV+ individuals undergoing treatment (HIV+HAART+). The second aspect was to optimize the ionization settings of the mass spectrometer. Quality control (QC) samples which comprised a pool of all samples used in the study [36] or a pool of representative samples from each condition being investigated (e.g. HIV negative, HIV+ and HIV+HAART+; [35] ) were prepared. The QC sample was infused into the inlet probe while scanning the TOF analyzer in both ESIPos and ESINeg ionization modes. Mass ions were observed in both modes and resulted in the optimization of both modes in regards to capillary voltage, cone voltage and extractor voltage. The trap voltage was set at 4 V to ensure that no unnecessary fragmentation would occur during ion transmission. The settings as detailed in the experimental section were found to provide the best ionization of the most compounds in both polarity modes and were used in all experimental work.
The third aspect evaluated was the stability of the method. QC samples were prepared and used to monitor the stability of sample runs during UPLC-MS analysis. A pooled sample was analyzed by doing ten consecutive injections on the same day and repeating the same analysis on the next day and comparing the two data sets. It was found that the UPLC column required three conditioning injections prior to starting the main analysis run. The results for the inter-day and intra-day experiments compared very well and ensured that extended sample runs would be possible even if the whole analysis run would span over several days. To minimize the effect of subtle changes in the separation over long analysis runs, all the samples were randomized in the sample table prior to analysis. Blanks were included to assess carryover and exclude possible contaminating ion features.
Optimized Metabolite Extraction from Sera using Ostro TM Plates
Ostro™ sample preparation plates (Waters Corporation, Milford, USA) and filtration through the Waters positive pressure-96 processor (Waters Corporation, Milford, USA) was utilized to facilitate serum metabolite extraction. Serum samples were thawed on ice prior to extraction to avoid loss of volatiles. Briefly, the Ostro TM plate was keyed onto a 96-well collection plate. One hundred microliters of sera, blanks and QC samples were randomly loaded onto the Ostro TM plate in duplicate, with a few exceptions as explained below which subsequently influenced the number of cases analyzed in electrospray ionization positive (ESI+) and negative (ESI-) mode respectively. Three hundred microliters of freshly prepared 1 % formic acid in acetonitrile was forcefully added to the plate wells and mixed through aspiration. The plate assembly containing sample and solvent was filtered under positive pressure at 414 kPa (60 psi). The collected filtrates in the collection plate were transferred on ice to the UPLC-MS facility for subsequent analysis. The initial conditions were 95% of A for 0.1 minute with a gradient profile 7 to 40% of A at 8 minutes, followed by a gradient profile 5 to 10% of A at 14 minutes and kept constant for 1 minute. The system was reequilibrated using the initial conditions with a total runtime of 20 minutes. The injection volume was set at 3 µl with triplicate injections acquired per sample. The PDA detector was scanned between 200 and 500 nm (1.2 nm resolution) and collected 20 spectra per second.
The SYNAPT G1 mass spectrometer was used in V-optics and operated in electrospray mode. Leucine enkephalin (50 pg/mL) was used as reference calibrant to obtain typical mass accuracies between 1 and 3 mDalton. Although positive ionization is commonly used and more compounds are ionized in this state [37] , the mass spectrometer was operated in both negative and positive mode of electrospray ionization to enable greater coverage of the metabolome for untargeted analysis. The capillary voltage was set at 2.0 kV, the sampling cone at 30 V and the extraction cone at 4 V. The micro channel plate detector voltage was set at 1950 V. The scan time was 0.1 seconds covering the 100 to 1000 Dalton (Da) mass range. The source temperature was 120 °C and the desolvation temperature set at 450 °C. Nitrogen was used as the nebulization gas at a flow rate of 800 L/h. MassLynx V4.1 (SCN 704) software was used to control the hyphenated system and for data manipulation. Figure S1 ) but LDA was found to be more appropriate in this case. The method used in the case of PCA was to compute principal components and then to do an LDA on the principal components. This was done because the method is commonly seen in the literature. In the case of LDA based on PCA, all the metabolites (n=1976 for ESI neg mode and n=2511 for ESI+ mode) are involved in the definition of each principal component. In the case of the LDA based on individual metabolites, stepwise discriminant analysis was used. Eleven and 10 metabolites selected by the stepwise procedure produced a 100% correct classification for ESI neg and ESI+ modes respectively. The model was not corrected for confounding factors, an aspect addressed under the discussion. The significance of these molecules were also verified through univariate analysis in the form of analysis of variance (ANOVA).
Data Processing and Statistical Analysis
Metabolite Identification
Mass spectral searches conducted using metabolite and/or structure databases and libraries 
RESULTS
Experimental Design and Sample Selection
To study metabolic complications, metabolites are often extracted from affected tissues and biofluids using laborious protocols which incorporate numerous handling steps ( Figure 1 ). As a result, variability is introduced into the data [38] . Utilizing a straightforward, easy to use extraction protocol with minimal handling steps should minimize the chances of obtaining erroneous data. A one-step protein precipitation and extraction protocol is presented here for use in UPLC-MS metabonomics experiments aimed at evaluating HIV and HAART-induced metabolic changes. Metabonomics using Ostro TM plates and UPLC-MS is also presented to show the unique detection of treatment-associated metabolites in infected biofluid.
The samples used in this study were well-matched in terms of gender and CD4 counts (Table 1 ). In the case of the treatment-naive HIV+ group, CD4 counts were relatively high and representative of an asymptomatic cohort. The HIV-infected cases were generally older and presented with varying viral loads. The possible influences of these confounding factors are elaborated on in the discussion.
Metabonomic Profiling
UPLC-MS base peak ion (BPI) chromatograms of HIV negative, HIV+ and HIV+HAART+ sera are shown in Figure 2 . Distinct, narrow chromatographic peaks suggest the successful detection of metabolites as well as the removal of phospholipids which previously masked the detection of metabolites when another extraction protocol was followed (see supplementary Figure S2 ). The chromatograms show the sera of the three groups exhibiting different metabolic profiles, notable by differences in their peak numbers and intensities Following integration and alignment of the MS data, LDA was applied to classify the groups as HIV negative, HIV+ and HIV+HAART+ and also to identify variables accounting for group differences. This statistical tool classified all cases correctly achieving 100% accuracy (Table 2 ) pre-and post cross-validation.
The number of participants was too small for a full cross-validation by means of a hold-out sample. Instead, the method applied was leave-one-out-at-a-time. Metabonomics data is multivariate and should ideally be analyzed using multivariate statistical approaches to increase the power of the analysis and avoid erroraneous conclusions [39] . ANOVA, applied to determine how well this statistics tool complemented mutlivariate stastics findings, detected many more metabolites that were significantly different between the groups than did LDA. Of the 21 important metabolites identified through LDA, 13 (62%) had p values < 0.05 (see Table 3 [i] and [ii])
indicating that ANOVA, in terms of the number of significantly altered molecules identified, complimented LDA findings to an extent.
Scatter plots (Figure 3) show maximum between-group separation, suggesting distinct metabolic profiles for each group. The metabolism of the treatment-experienced group was most affected as seen by how far this group is positioned from the HIV negative and HIV+ groups ( Figure 3 ) with the greatest separation achieved along the first discriminant. In Figure 2 there are visual similarities between the metabolism of the HIV negative and HIV+ group which indicate that the infected individuals to still be relatively healthy. This was further amplified in the scatter plots ( Figure 3 , along the first discriminant). If group separation is evaluated along the second discriminant, it appears that the metabolic profile of the HIV+HAART+ group shifts toward that of the HIV negative group. Within-group metabolic differences were minimal and representative of a homogeneous group of samples. Reliability and validity of the MS runs were also confirmed through the tight clustering of QC samples and tight clustering of technical repeats (finally averaged to allow for LDA).
Following LDA, important variables (n=21) contributing to the clustering of the experimental groups in ESI negative and ESI+ mode were identified (Table 3 [i] and [ii]). Serum contains 90% water and mainly has polar metabolites [40] . In this study, each ionization mode resulted in the detection of unique metabolites. In the ESI-mode (Table 3 [i]) metabolites involved in lipid and/or membrane biosynthesis as well as nucleotide metabolism were mainly identified. Metabolites related to the treatment of HIV-associated conditions as well as amino acid and protein metabolism were mainly identified in ESI+ mode (Table 3 [ii]). If the assumption is that the metabolite levels in uninfected sera are normal then the 21 distintinguishing metabolites showed either infection or infection and HAART as being responsible for the shifts/changes in the levels of these molecules ( Figure 4 ).
DISCUSSION Experimental Design and Sample Selection
During random sample selection, the influence of possible confounding factors must be considered, because these factors may account for metabolic differences and influence the clustering of samples. For our dataset; age, gender and the varying viral loads of patients did not appear to be confounding since samples grouped according to these parameters failed to cluster together. When the possible confounder, gender, was included as a variable in the LDA model (see supplementary Figure S3 ), it did not affect the data. Similarly, when age was applied to the model, it did not play a significant role in the results. In a non-HIV biofluid metabonomics study, Tulipani et al (2013) [31] concluded that solvent extraction in combination with Ostro TM plates, as also used in our study, allowed for subtle metabolic changes between groups, independent of confounding factors, to be observed. A truly randomized sample set should have included the same age across experimental groups. However, being at the mercy of the volunteer approach, we were limited to using only patients who agreed to involvement and it turns out those younger individuals totally sure of their status only volunteered when negative. As mentioned, the LDA model not responding to gender or age gave the confidence to continue the study. In addition, the fact that infected individuals with differing ages ( Table 2 , mean age of HIV+ and HIV+HAART groups) separated based on metabolites, strongly supports the validity of the collected data.
Metabonomics Profiling, Perturbed Metabolites and their Biological Significance
The body largely depends on oxidation processes for its energy supply. This occurs mainly through the breakdown of fats, carbohydrates and amino acids in mitochondria and peroxisomes. HIV, the immune response to infection and treatment disrupts host metabolism. In our findings, treated patients were most differentiated from the HIV negative and HIV+ groups (Figure 2 and In addition, metabolites associated with the treatment of HIV-associated conditions were also observed. HIVinduced disruption of fatty acid/lipid metabolism which is usually associated with lipodystrophy (fat redistribution) is well-documented in the literature [8, [11] [12] [13] [14] as is the disruption of carbohydrate and energy metabolism [22, [41] [42] [43] .
To get a better idea of the contribution of HIV and/or treatment to the measured metabolic alterations, changes in the levels of the respective metabolites were evaluated through mean plots (Figure 4 ). Of the 21 metabolites identified through LDA as contributing to group differences; 3 (14.3%) were altered due to HIV, 5 (23.8%) were altered due to HAART while 13 (61.9%) were altered as a result of infection and treatment. The plots confirmed infection and treatment to augment metabolic alterations and also reflects the strong influence of HAART on the metabolic profile of the cohort under investigation. Upon reviewing patient records, it was found that of the HAART combinations given to patients, a large percentage of individuals were on combinations of nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs, Table 1 ). These regimens are known for causing mitochondrial dysfunction, lipodystrophy and lactic acidosis [44] [45] [46] . HIV-infected cells and lipolysis, which is a common feature of infected individuals, require increased amounts of energy and therefore functional mitochondria for this purpose. Studies have shown early on that HIV-infected cells have higher rates of resting energy expenditure [41, 42] which is in keeping with the high energy demands of infected cells. Mitochondria drive metabolic processes [47] and together with the Krebs cycle serves as the "hub" of cellular metabolism. The human immunodeficiency virus obtains energy mainly by altering host metabolic processes by impacting for example, mitochondria [43] . If compromised, as occurs during HIV infection, energy processes are affected such that adenosine triphosphate (ATP) is depleted and glycolysis activated [48] . This disruption in energy metabolism is evident by the alteration in carbohydrate metabolism detected in our study. Because of the role of this organelle in producing ATP, energy metabolism is ultimately affected. Several metabolites, for example, cytidine triphosphate (Table 3 [i]) and 1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycerol 3-diphosphate (Table 3 [ A closer evaluation of the mean plots in Figure 4 could add to our understanding of the mechanisms of HIV and/or HAART-induced metabolic complications. Since most of the metabolic changes involved lipid changes and were as a result of HAART as well as the synergy between infection and treatment, the changes may suggest a mechanism used by the virus to ensure its survival depending on whether the levels of these molecules are increased or decreased. For example, the virus depends on the host's metabolic machinery to survive. It can therefore induce an increase in metabolites involved in lipid and membrane biosynthesis (e.g. Figure 4 [i], identified as Methyl dodecanoate in Table 3 [i]) as well as cell formation ensuring it has a host in which to replicate. Alternatively, the increase in cell turnover may be a host response to infection in order to produce more cells to ward off the virus. A decrease in the levels of this metabolite following the administration of HAART suggests an opposing effect by treatment to restore the level of the metabolite to that of uninfected controls. Whether the shift implies successful therapeutic intervention would require further investigation. Similarly, the remaining plots can be evaluated in this manner but quantitative analysis would be more informative.
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Metabolites Indicative of Treatment
Of the metabolites detected, there were also indications of changes in nucleotide, amino acid and protein metabolism. Nucleotides serve as the building blocks for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis. That nucleotide metabolism is affected in the host is in agreement with the life cycle of the virus i.e. HIV integrating its genetic information into that of the host. Nucleotides serve as energy carriers, cell signalling molecules and cofactors to various reactions. A disruption in the metabolism of these molecules thus adds to the disruption in cell signalling already induced by HIV and/or its treatment. Nucleotide metabolism in the context of HIV infection is important because HIV cannot encode nucleotide-metabolizing enzymes and it's intracellular replication requires a continous supply of deoxynucleotidetriphosphate (dNTPs, [49] ).
Proteins serve important biological roles including catalyzing metabolic reactions, assisting with DNA replication, initiating responses to stimuli and transporting molecules from one location to another. An alteration to amino acid and protein metabolism coincides with the change in nucleotide metabolism which is required for the replication of genetic information. It also confirms a disruption in cell signaling processes highlighted previously to occurr as a result of changes in lipid and membrane biosynthetic processes.
Anemia is a documented complication of HIV infection associated with decreased patient survival [50] .
We identified metabolites potentially related to the treatment of anemia and sickle cell disease suggesting the occurrence of these conditions in patients. As shown in [50] to be a predictor for the progression of HIV/AIDS. Leucovorin was detected in the ESImode. After tracing the variable (in this case V1367MZ458.1292) in the dataset using individual metabolite trend plots prepared in MassLynx v4.1 software, this variable was found to be present in mostly treated patients allowing us to infer the presence of a specific condition and its treatment in those patients. Looking at the particular patient's files where the variable was present, we were able to confirm that the patient was receiving treatment for anemia. We detect breakdown products of hemoglobin which serve as markers for urinary tract function. Hemoglobin breakdown products such as globin are known to be converted to amino acids which participate in metabolism or the formation of new proteins. It is quite interesting to observe how metabolites of blood-related conditions coincide with protein metabolism changes noted in the preceding paragraph.
Psoriasis is a skin condition associated amongst others, with HIV infection. This condition is associated with cardiovascular disease, a common complication of HIV-infected and treated individuals [51] . In this study we detect DHNA, an anthraquinone used to treat psoriasis. Other therapeutics given to the HIV+ individuals of this study include for example antifungal agents such as clotrimazole. Immunocompromised patients are burdened with opportunistic infections making the detection of metabolites which are linked to these types of therapeutics valid. We also detected metabolites suggesting the use of anti-inflammatory, anti-pyretic and antirheumatic agents used to treat common HIV-related conditions. HIV-infected individuals are known to be under oxidative stress [52] . We detected 5'deoxyadenosine which is a marker of oxidative damage. Taxifolin and chlorogenic acid have antioxidant properties and were also detected implying a counter response to oxidative stress. In a gas chromatography mass spectrometry (GC-MS) metabonomics study investigating HIV-induced mitochondrial dysfunction in asymptomatic HIV-infected patients, Williams et al (2012) [3] detected two metabolites linked to "self-treatment". GC-MS detects volatile compounds [53] . Most metabolites in nature are polar and non-volatile [53] as is the metabolites of sera [40] . Because GC requires samples to be volatile, the process of volatilization could have contributed to the failure to detect more "self treatments" by the technique.
Inferring the treatment of HIV-related complications was made here after tracking the specific metabolite back to the actual sample in the dataset and reviewing the patient's status i.e. HIV negative, HIV+ and/or HIV+HAART+. Where treatment related metabolites were detected, the patients were treatment-experienced.
Metabonomics therfore has the potential to provide real phenotypic patient information.
These findings imply that SPE in the form of Ostro TM plates is recommended for biofluid metabolome extraction because it eliminates large molecules (proteins and phospholipids) that have been shown to mask metabolites that are analyzed using UPLC-MS. Ultra performance LC-MS proved ideal for biofluid metabonomics because of its increased sensitivity and resolution to detect subtle metabolic disturbances. Based on data presented here the approach could find use in biomarker identification and therefore disease diagnosis and prognosis as well as HIV/AIDS management i.e. monitoring adherence to treatment, treatment success/failure and linking specific drugs to specific metabolic complications.
CONCLUSION
Shown here for the first time is an easy SPE protocol which allowed for the collection of reproducible, reliable UPLC-MS data which in turn distinguished HIV-influenced compared to therapy-induced metabolic changes. UPLC-MS detected changes in lipid and energy metabolism in negative ionization mode whilst metabolites indicative of the treatment of HIV-associated conditions were mainly evident in positive ionization mode. The biological role of the metabolites causing group differentiation coincides well with that reported in the literature. The mean plots already gave an indication of an increase or decrease in metabolite levels while chemometrics confirmed the visual observations. The quantification of metabolite changes as a necessary next step will be simplified by either a targeted analysis or a decision on the specific metabolite or groups of metabolites to investigate in order to identify useful standards and/or molecules for sample spiking.
Quantification should contribute to the clarification of the exact HIV-related mechanisms involved in metabolite increases or decreases. This study presented an easy sample preparation protocol designed for minimal sample
handling that favoured quality metabonomics data collection, which is important for clinically relevant biomarker identification. The end use of mass spectrometric metabonomics should eventually be a clinical application, detecting biomarkers of value in diagnostics, prognostics or disease management. The detection of metabolites related to therapy implies a strong role for MS-metabonomics in HIV/AIDS management by monitoring the success/failure of specific treatment regimens, patient adherence and linking specific treatment regimens to particular metabolic complications. The ability to infer additional information from the data suggests an added advantage to metabonomics, in particular the ability to screen randomly and then go back to the sample group and determine whether the conclusions/inferences correlate to the patient's reality. 
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